Wockhardt Ltd 2024 AR2
The report highlights Wockhardt Limited's performance for the fiscal year 2023-2024, during which the company achieved a consolidated revenue of ₹2,881 crore. Key achievements include the successful completion of the pivotal Phase 3 pneumonia study for its novel macrolide antibiotic Nafithromycin (WCK 4873) and the successful raising of ₹480 crore through a Qualified Institutional Placement (QIP) to fund clinical R&D. Additionally, the company's patented novel antibiotics EMROK and EMROK O gained wider clinical acceptance, treating over 65,000 patients. On the sustainability front, the company implemented zero liquid discharge at multiple facilities and reduced its Scope 1 and Scope 2 emissions.
Company: Wockhardt Ltd
Sector: Manufacturing
Country: India
Year: 2024
Type: AR2
Pages: 268
Back to company
Wockhardt Ltd
Annual Report
The report highlights Wockhardt Limited's performance for the fiscal year 2023-2024, during which the company achieved a consolidated revenue of ₹2,881 crore. Key achievements include the successful completion of the pivotal Phase 3 pneumonia study for its novel macrolide antibiotic Nafithromycin (WCK 4873) and the successful raising of ₹480 crore through a Qualified Institutional Placement (QIP) to fund clinical R&D. Additionally, the company's patented novel antibiotics EMROK and EMROK O gained wider clinical acceptance, treating over 65,000 patients. On the sustainability front, the company implemented zero liquid discharge at multiple facilities and reduced its Scope 1 and Scope 2 emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees